Figure 5.
In vivo activity of IL4/7 ChR transgenic T cells in the presence of IL4-producing tumors. Severe combined immunodeficiency mice engrafted subcutaneously with FFluc-positive EBV-LCLs engineered to produce IL4 (5 × 106/animal) were subsequently divided into four groups. A control group did not receive any T cells (tumor alone: open square), whereas the remaining mice were treated with (i) NT T cells without additional cytokines (NT T cells: triangle with gray shading), (ii) NT T cells with exogenous IL2 provided three times weekly (NT T cells + IL2: black triangle), or (iii) IL4/7 ChR T cells without exogenous cytokines (4/7R T cells: red circle). Panel (a) shows tumor growth as monitored using an in vivo imaging system and reported as fold change in bioluminescence, and panel (b) shows tumor volume (mm3) as measured using calipers. (c) The long-term survival advantage provided by IL4/7 ChR transgenic T cells. (d) Bioluminescence images of representative mice from the tumor alone group as well as animals receiving either NT or IL4/7 ChR T cells. (e) The CT imaging performed on the same animals, whereas panel (f) shows the bioluminescence/CT overlay.